Amundi Increases Stake in Baxter International Inc. $BAX

Amundi grew its holdings in shares of Baxter International Inc. (NYSE:BAX - Free Report) by 9.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,444,705 shares of the medical instruments supplier's stock after buying an additional 125,431 shares during the quarter. Amundi owned 0.28% of Baxter International worth $45,292,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Horizon Investments LLC grew its holdings in shares of Baxter International by 5.0% during the first quarter. Horizon Investments LLC now owns 7,438 shares of the medical instruments supplier's stock valued at $255,000 after buying an additional 351 shares during the last quarter. Rothschild Investment LLC grew its holdings in shares of Baxter International by 3.4% during the first quarter. Rothschild Investment LLC now owns 14,479 shares of the medical instruments supplier's stock valued at $496,000 after buying an additional 481 shares during the last quarter. Archer Investment Corp grew its holdings in shares of Baxter International by 20.5% during the first quarter. Archer Investment Corp now owns 2,935 shares of the medical instruments supplier's stock valued at $100,000 after buying an additional 500 shares during the last quarter. Home Federal Bank of Tennessee grew its holdings in shares of Baxter International by 2.5% during the first quarter. Home Federal Bank of Tennessee now owns 22,600 shares of the medical instruments supplier's stock valued at $774,000 after buying an additional 550 shares during the last quarter. Finally, Private Trust Co. NA grew its holdings in shares of Baxter International by 17.3% during the first quarter. Private Trust Co. NA now owns 3,822 shares of the medical instruments supplier's stock valued at $131,000 after buying an additional 565 shares during the last quarter. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on BAX shares. UBS Group reduced their price objective on shares of Baxter International from $35.00 to $24.00 and set a "neutral" rating for the company in a report on Monday, August 4th. Evercore ISI cut their price target on shares of Baxter International from $44.00 to $42.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Morgan Stanley cut their price target on shares of Baxter International from $28.00 to $27.00 and set an "underweight" rating on the stock in a report on Tuesday, July 15th. The Goldman Sachs Group downgraded Baxter International from a "buy" rating to a "neutral" rating and set a $25.00 target price on the stock. in a research note on Friday, August 1st. Finally, Citigroup lowered their price objective on shares of Baxter International from $34.00 to $32.00 and set a "neutral" rating on the stock in a research report on Wednesday, July 9th. Three research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Baxter International presently has a consensus rating of "Hold" and a consensus target price of $30.11.

Baxter International Price Performance

Baxter International stock traded down $0.49 during midday trading on Friday, reaching $24.01. 1,592,225 shares of the stock were exchanged, compared to its average volume of 5,369,748. The company's fifty day moving average is $25.74 and its 200-day moving average is $29.48. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.49 and a current ratio of 2.30. The firm has a market cap of $12.33 billion, a PE ratio of -80.02, a PEG ratio of 0.78 and a beta of 0.61. Baxter International Inc. has a 52 week low of $21.33 and a 52 week high of $40.49.

Baxter International (NYSE:BAX - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 earnings per share for the quarter, missing analysts' consensus estimates of $0.60 by ($0.01). The firm had revenue of $2.81 billion for the quarter, compared to the consensus estimate of $2.82 billion. Baxter International had a positive return on equity of 16.96% and a negative net margin of 1.42%.The business's revenue was up 4.3% on a year-over-year basis. During the same period last year, the company posted $0.68 EPS. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. On average, sell-side analysts forecast that Baxter International Inc. will post 2.48 EPS for the current year.

Baxter International Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 1st. Investors of record on Friday, August 29th will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Friday, August 29th. Baxter International's dividend payout ratio is currently -226.67%.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.